rs121918385 — APOB APOB Glu4034fs

Frameshift deletion in APOB that truncates apolipoprotein B, causing familial hypobetalipoproteinemia — very low LDL cholesterol with cardiovascular protection but hepatic steatosis risk

See your personal result for APOB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APOB Frameshift — The Rare Mutation That Slashes LDL and Rewires Liver Fat

Apolipoprotein B (apoB) is the structural backbone of every VLDL and LDL particle in your bloodstream. Without functional apoB-100, the liver cannot package and export fats into the circulation. The rs121918385 variant is a 1-base-pair deletion in APOB exon 26 that truncates the apoB protein at approximately position 4040 — producing a severely shortened protein that cannot be lipidated or secreted normally. Carriers are clinically defined as having familial hypobetalipoproteinemia (FHBL)11 familial hypobetalipoproteinemia (FHBL)
a dominantly inherited disorder characterized by LDL cholesterol below the 5th percentile for age and sex, typically 20–50 mg/dL in heterozygotes.

The Mechanism

The deletion removes a single cytosine from the glutamic acid codon at position 4034, shifting the reading frame. The altered sequence encodes arginine at position 4034 then hits a premature stop codon seven residues later (p.Glu4034ArgfsTer7). The truncated mRNA is partially degraded by nonsense-mediated decay22 nonsense-mediated decay
a cellular surveillance mechanism that destroys transcripts with premature stop codons, reducing total functional apoB-100 output from the mutant allele. What survives is a shortened protein representing roughly 88% of full-length apoB that cannot be efficiently assembled into VLDL particles.

Linton, Pierotti & Young 199233 Linton, Pierotti & Young 1992
Reading-frame restoration with an apolipoprotein B gene frameshift mutation. PNAS 89(23):11431–5 described the molecular mechanism in detail and observed an unusual compensatory feature: transcriptional slippage at the polyadenosine stretch created by the deletion can occasionally insert an extra adenine, restoring the reading frame and allowing some full-length apoB to be produced from the mutant allele. This partial compensation is why the phenotype is less severe than complete absence of apoB.

The Evidence

Cardiovascular protection. The most clinically striking consequence of APOB truncating variants is profound protection against coronary heart disease. Peloso et al. 201944 Peloso et al. 2019
Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circ Genomic Precis Med sequenced APOB in 57,973 participants (18,442 with early-onset CHD, 39,531 controls). Carriers of any APOB protein-truncating variant had 43 mg/dL lower LDL-C and 72% lower risk for CHD (OR 0.28, 95% CI 0.12–0.64, P=0.002). This is the strongest genetic evidence that lifelong low LDL directly prevents coronary disease.

Hepatic fat accumulation. Fat that cannot be exported as LDL accumulates in the liver. Heterozygotes have a 3–5 fold increase in hepatic fat content compared to controls and a 54% prevalence of hepatic steatosis on ultrasound in longitudinal studies. Progression to steatohepatitis, fibrosis, or cirrhosis is uncommon but occurs in approximately 5–10% of heterozygotes, particularly in those with additional metabolic risk factors such as high caloric intake or alcohol use.

Fat-soluble vitamins. Because fat absorption depends partly on LDL-sized particles for vitamin transport from the gut, heterozygotes have measurably lower plasma vitamin E levels (~50% of controls in Clarke et al. 200655 Clarke et al. 2006
Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. Clin Chem 52(7):1339-45). However, the same study found no increase in oxidative stress biomarkers, and concluded that routine vitamin E supplementation is not warranted for heterozygotes. In biallelic (homozygous) carriers, fat-soluble vitamin deficiency is severe and requires high-dose supplementation.

Practical Actions

Heterozygous carriers benefit primarily from cardiovascular surveillance to confirm the expected protection is present, and liver monitoring to detect the minority who develop clinically meaningful steatosis. The actionable difference from the general population is threefold: (1) cardiovascular risk scoring should be recalibrated because standard LDL-based risk equations substantially overestimate risk at these LDL levels; (2) liver health — not lipid-lowering — becomes the primary metabolic concern; (3) fat-soluble vitamin levels should be checked periodically given reduced plasma transport.

Homozygous carriers (extremely rare, prevalence <1:1,000,000) require subspecialty management with high-dose fat-soluble vitamins and low-fat dietary modification — essentially the same protocol as abetalipoproteinemia.

Interactions

APOB-FHBL heterozygosity can occur alongside APOE variants (rs429358, rs7412) that affect LDL clearance via an independent receptor pathway. In compound carriers of APOB-FHBL and APOE4, the APOE4-driven impairment of LDL receptor binding partially offsets the APOB production deficit — LDL levels may be in the low-normal range rather than very low, potentially obscuring the FHBL diagnosis on routine lipid panels and warranting apoB protein electrophoresis to detect the truncated isoform.

Nutrient Interactions

vitamin E reduced_absorption
vitamin A reduced_absorption
vitamin D reduced_absorption
vitamin K reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

CC Non-carrier Normal

No APOB frameshift — standard lipoprotein assembly and LDL levels

You do not carry the rs121918385 frameshift deletion. Your APOB gene produces full-length apolipoprotein B-100, supporting normal VLDL and LDL assembly and secretion. This is the genotype present in virtually all people globally (over 99.99% of the population).

CD FHBL Carrier Carrier

One APOB frameshift copy — very low LDL with hepatic steatosis risk

Heterozygous APOB-FHBL is estimated to affect approximately 1 in 3,000 people when all truncating APOB variants are considered, though this specific frameshift is considerably rarer. The variant follows an autosomal codominant pattern: one copy gives an intermediate phenotype (half-normal apoB output), not just carrier status. The cardiovascular protection is real and substantial — APOB truncating variants are associated with 72% lower coronary heart disease risk in large population studies. The primary medical concern is the liver: hepatic triglyceride accumulates because fat that cannot be exported as VLDL/LDL is retained. Studies show 3–5x higher liver fat content in heterozygotes, and roughly 5–10% develop clinically significant steatohepatitis over time. Plasma vitamin E levels are measurably lower (~50% of controls) but oxidative stress markers are not elevated, and routine vitamin E supplementation is not standard practice for heterozygotes.

DD Homozygous FHBL Homozygous

Two APOB frameshift copies — severe hypobetalipoproteinemia requiring specialized management

Biallelic APOB-FHBL resembles abetalipoproteinemia in severity, though the presence of some residual apoB activity (from transcriptional slippage and read-through) produces a less catastrophic phenotype than complete MTTP deficiency. Hepatic steatosis is universal and severe. Fat-soluble vitamins cannot be adequately absorbed because chylomicron assembly and secretion from intestinal enterocytes is similarly impaired. Clinical management mirrors abetalipoproteinemia protocols: strict dietary fat restriction to reduce gastrointestinal fat load while maintaining caloric intake, combined with high-dose fat-soluble vitamin supplementation. Growth, neurological function, ophthalmology, and bone density require regular surveillance. Women of reproductive age must reduce vitamin A doses by 50% during pregnancy due to teratogenicity at high doses.